Newer developments in the immunotherapy of malignant melanoma - PubMed (original) (raw)

Review

Newer developments in the immunotherapy of malignant melanoma

Benjamin Maslin et al. J Oncol Pharm Pract. 2014 Feb.

Abstract

Individuals with malignant melanoma present a variety of immune abnormalities including but not limited to cellular immune dysfunction, antigen presentation deficits, and cytokine production defects. Therefore, enhancing the immune system potential represents an appealing avenue for melanoma therapy. The authors review the immune therapies currently in clinical use as well as the most promising immunotherapy candidates. Ipilimumab, a monoclonal antibody against the CTLA-4, was approved for the therapy of advanced melanoma in 2011. In addition, sizeable anti-melanoma activity has recently been shown with the use of other agents including anti-PD-1/anti-PD-1 ligand antibodies. Consequently, these experimental immunotherapy agents may soon become important items in the anti-melanoma armamentarium.

Keywords: Malignant melanoma; anti-CTLA-4 antibodies; anti-PD-1 antibodies; immunotherapy; ipilimumab.

PubMed Disclaimer

Publication types

MeSH terms

Substances

LinkOut - more resources